research chemical is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-03-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, dark | Protect from repeated temperature changes. |
| Common analytical method | LC-MS or HPLC-UV | Reference standard required for comparison. |
| Common synonyms | SR9009; Stenabolic; REV-ERB agonist | Vendor naming may vary. |
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
It has also been discovered that mRNA secondary structure is important for cell processes such as transcript stability and translation. The general idea is that the functional domains of mRNA fold upon each other, while the start and stop codon regions generally are more relaxed, which could aid in the signaling of initiation and termination in translation. If the oncoming ribosome pauses because of a knot in the RNA, then the polypeptide could potentially have enough time to fold into a non-native structure before the tRNA molecule can add another amino acid. Silent mutations may also affect splicing, or transcriptional control.
==== Niche uses ==== There are thousands of uses of various potassium compounds. One example is potassium superoxide, KO2, an orange solid that acts as a portable source of oxygen and a carbon dioxide absorber. It is widely used in respiration systems in mines, submarines and spacecraft as it takes less volume than the gaseous oxygen.
In daily life, little people face numerous obstacles because the environment is tailored to average-sized individuals. Some little people can only use ATMs, kitchens, toilets, and sinks with aids. Low stools and step stools play a special role, as they can be used in various ways to bridge the height difference. Stools are also useful as footrests while sitting, as the legs of short people dangle in the air when sitting on an average chair, which can be painful and uncomfortable in the long run and may hinder fine motor skills during work. To be mobile, some individuals use customized scooters or bicycles, as it can be problematic, depending on the type of short stature, to walk longer distances. With specially adapted vehicles, most individuals of short stature can drive without further hindrances. Generally, pedal extensions and an individually adjusted seat at the correct height are required. Some individuals with dwarfism are tall enough to drive without pedal extensions. Usually, patients with skeletal dysplasia with limited mobility can receive allowances or grants for vehicle assistance through governmental help or rehabilitation providers.
== Awards and honours == Beynon received the Sigma Xi Research Award, Purdue University in 1973, the Marice F. Hasler Award in 1979, the Jozef Stefan Medal in 1980, the Medal of the Serbian Chemical Society in 1981, the Techmart Trophy of the British Technology Group in 1984, the Jan Marc Marci Medal, Czechoslovak Spectroscopic Society in 1984, the International Mass Spectrometry Society Thomson Medal in 1985, the American Chemical Society Field and Franklin Award for Outstanding Work in Mass Spectrometry in 1987, the British Mass Spectrometry Society Aston Medal in 1998, and the Italian Mass Spectrometry Society Gold Medal in 1990. He was the Founder chairman British Mass Spectrometry Society (1960), a founding member of the American Society for Mass Spectrometry (1967), and Founder President of the European Mass Spectrometry Society (1993). Beynon was elected to the Royal Society in 1971. He authored over 350 scientific publications. and several books on mass spectrometry. In 1987, Beynon was founding editor-in-chief of the journal Rapid Communications in Mass Spectrometry.
Sources: en.wikipedia.org
== Hydrogen-4 == 4H (atomic mass 4.02643(11) Da), with one proton and three neutrons, is a highly unstable isotope. It has been synthesized in the laboratory by bombarding tritium with fast-moving deuterons; the triton captured a neutron from the deuteron. The presence of 4H was deduced by detecting the emitted protons. It decays by neutron emission into 3H with a half-life of 139(10) ys (1.39(10)×10−22 s). In the 1955 satirical novel The Mouse That Roared, the name quadium was given to the 4H that powered the Q-bomb that the Duchy of Grand Fenwick captured from the United States.
Large randomised controlled trials have shown that dapagliflozin significantly reduces worsening heart failure and heart failure hospitalisation across the spectrum of heart failure, including patients with reduced ejection fraction (LVEF <40%), mildly reduced ejection fraction (LVEF 41–49%) and preserved ejection fraction (LVEF ≥50%). Research shows that early initiation during hospitalization for acute heart failure appears safe in stable patients. Combined results of multiple trials also found that starting SGLT2 inhibitors in the hospital significantly lowers the risk of death from heart problems and prevents heart failure from getting worse. Dapagliflozin and other SGLT2 inhibitors may reduce hospitalisation for heart failure in Type 2 diabetic patients, with or without atherosclerotic cardiovascular disease,however evidence across these patient groups remains incomplete. Some meta-analyses and cohort studies have demonstrated consistent efficacy among SGLT2 inhibitors in reducing specific heart failure hospitalization, but there are no direct and definitive studies indicating the superiority of dapagliflozin over other SGLT2 inhibitors like empagliflozin and further studies are needed to support this claim In the European Union, dapagliflozin is indicated in adults for treatment of:
=== Amino acid deficiencies === In bacteria and yeast, codon reassignment can be caused by a shortage of required amino acids. Instead of halting protein production all together, tRNA molecules select another amino acid to add to the amino acid chain. This amino acid may have similar properties to the intended amino acid, or it may not. This may cause deformities in the proteins, making them less efficient or even nonfunctional. A hypothesis as to why this phenomenon persists despite the loss of efficiency is that it is preferable for the organism to have a worse version of the protein than to have no protein at all. In some human cancer cells, such as melanoma cells, a similar tactic is used. As an immune response, to try and destroy the cancer, T cells release an enzyme that destroys the essential amino acid tryptophan within the cancer cells. This typically deprives the cancer of many key proteins, killing the cancer cells. However, some cancer cells are able to use codon reassignment to replace the tryptophan with a similar amino acid called phenylalanine. This amino acid replacement and resulting functional protein allows the cancer cell to survive and continue dividing.
Sources: en.wikipedia.org
=== Venom toxicity === The black mamba can inject 100–120 mg venom in one bite. Comparing the LD50 results with the amount of venom that can be injected shows that one bite is fatal. For humans a dose of 10–15 mg is enough to be fatal.
=== 2 May === Russia claimed to have taken Berdychi, near Avdiivka. It also claimed to have shot down a drone over Crimea. Two people were killed in separate Russian attacks in Donetsk and Kharkiv Oblasts.
=== Pakistan === In Pakistan, the National Institute of Health (NIH) in Islamabad is the pioneer in laboratory sciences. The College of Medical Lab Technology (CMLT) of the NIH offers a two-year F.Sc degree in Medical Lab Technology (MLT). The previous two-year B.Sc. in MLT was discontinued and replaced by the four-year Bachelor Program in Medical Lab Sciences (MLS). The University of Health Sciences in Lahore also offers a four-year Bachelor program in MLS through approved colleges. The University of Lahore, University of Faisalabad, University of Sargodha, and Superior University in Lahore all offer a five-year Doctor of Medical Lab Sciences (DMLS) Program. Eligibility criteria for the four-year B.Sc. in MLS and the five-year Doctor of Medical Lab Sciences (DMLS) is the F.Sc. Pre-Medical.
Sources: en.wikipedia.org
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.
The solid is usually kept desiccated at -20 °C or lower and protected from light. Stock solutions are aliquoted to limit freeze–thaw cycles. Aqueous solutions are not generally recommended for long-term storage.
Laws differ by country and by intended use. It is not an approved medicine, and many vendors sell it as a research chemical. Purchasers are responsible for confirming local restrictions.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.